<DOC>
	<DOCNO>NCT00360906</DOCNO>
	<brief_summary>Based previous clinical study indicate beneficial treatment effect omega-3 fatty acid multiple sclerosis , increase evidence anti-inflammatory effect omega-3 fatty acid , study aim evaluate treatment effect concentrate omega-3 fatty acid ( Triomar™ ) MS , monotherapy combination standard immunomodulatory therapy define interferon-beta 1a ( Rebif™ ) .</brief_summary>
	<brief_title>Omega-3 Fatty Acid Treatment Multiple Sclerosis</brief_title>
	<detailed_description>Patients relapsing-remitting multiple sclerosis evidence disease activity define least one relapse least one new MRI lesion year prior inclusion include study . Eligible patient randomise daily treatment either oral omega-3 fatty acid ( Triomar™ ) placebo . After six month patient addition receive interferon-beta 1a ( Rebif™ ) 44 mcg subcutaneous three time per week another 18 month . The patient undergo monthly contrast enhance MRI first nine month thereafter month 12 24 . They also examine clinical laboratory test six month interval addition month 9 ( 3 month start IFNB treatment ) . Fatigue QoL registration perform baseline month 6 , 12 24 . Tests circulate neutralising antibody interferon-beta perform study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>A patient may include he/she ; Is age 18 55 year ( include ) . Has multiple sclerosis accord McDonald criterion ( McDonald 2001 ) Has stable disease last month period prior inclusion , disability equivalent EDSS 5.5 le ( Kurtzke 1983 ) . Has show disease activity define least one relapse least one new MRI lesion ( T1 enhance T2 lesion – ref . McDonald criterion ) year prior inclusion . Is prepared consider able follow protocol attend plan visit whole study period . Is use adequate contraceptive method negative pregnancy test result ( female childbearing potential must ) . Has give write informed consent . A patient exclude he/she ; Has receive continuous oneweek treatment unsaturated fatty acid ( omega3 ) within 3 month prior inclusion study . Has active RRMS disease would strongly recommend standard immunomodulatory treatment treat neurologist . Has receive treatment interferonbeta glatiramer acetate within 6 month prior inclusion study . Has receive treatment lymphoid irradiation , mitoxantrone , cyclophosphamide longterm glucocorticoid . Has receive treatment azathioprine , cyclosporine immunosuppressive agent within year prior inclusion study . Has receive treatment glucocorticoid ACTH within two month prior inclusion study . Has experience relapse within one month prior inclusion study . Has convert secondary progressive MS. Has suffer major depression psychiatric disorder would preclude safe participation protocol . Has diabetes mellitus . Has alcohol drug abuse . Has cardiac insufficiency , cardiomyopathy , significant cardiac dysrhythmia , unstable advanced ischemic heart disease ( NYHA III IV ) , malignant hypertension . Has renal insufficiency . Has ASAT ALAT &gt; 2,5 x normal upper limit . Has leukopenia &lt; 2500 leukocytes per µl thrombocytopenia &lt; 100 000 thrombocyte per µl . Has systemic disease , influence his/her safety compliance , evaluation disability . Has thromboembolic disease need anticoagulative treatment . Have formerly show severe reaction study drug , interferonbeta gadolinium ( MRI contrast ) . Is breastfeed pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>RRMS</keyword>
	<keyword>Omega-3</keyword>
	<keyword>Treatment</keyword>
</DOC>